Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Carfilzomib-Based Quadruplet Regimen Beats Triplet Approach in Newly Diagnosed Myeloma

Induction with the quadruplet regimen of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) led to deeper responses and longer progression-free survival (PFS) in patients with...
On location

Subcutaneous and Intravenous Daratumumab Have Similar Safety, Efficacy in Previously Treated and Newly Diagnosed...

A subcutaneous formulation of daratumumab, plus standard-of-care treatment, led to response rates that were similar to those seen with intravenous daratumumab in patients with...
On location

Can Immunomodulatory Drugs Overcome CHIP’s Effects in Post-Transplant Multiple Myeloma?

Patients with multiple myeloma (MM) who harbor somatic mutations in hematopoietic cells, known as clonal hematopoiesis of indeterminate potential (CHIP), have better post–autologous hematopoietic...
On location

Examining Pregnancy Outcomes in Eculizumab-Treated Women With Atypical Hemolytic Uremic Syndrome

Women with atypical hemolytic uremic syndrome (aHUS) treated with eculizumab have similar pregnancy outcomes to women who were not treated with eculizumab, according to...
On location

Patients With Hemophilia B Report Poor Bleeding Control With Extended Half-Life Factor IX Products

Extended half-life factor IX (FIX) products have been designed to prolong the time between clotting factor injections for patients with hemophilia B, but an...
On location

Two Studies Support Using Concizumab as Prophylaxis in Patients With Hemophilia

Concizumab could be a safe and effective subcutaneous prophylactic treatment option for patients with hemophilia A or B with or without inhibitors, according to...
On location

Hemophilia B: The Next Target for Gene Therapy?

Treatment with a single dose of AMT-061, an investigational gene therapy, led to increased factor IX (FIX) activity and reduced spontaneous bleeding episodes for...
On location

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

The combination of isatuximab and pomalidomide plus dexamethasone (Pd) extended progression-free survival (PFS) to 11.5 months in patients with relapsed/refractory multiple myeloma (MM) –...
On location

Guadecitabine Performs No Better Than Other Hypomethylating Agents in Treatment-Naïve Acute Myeloid Leukemia

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) show that this...
On location

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A

In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates...
Advertisement

Current Issue

November 2019, Volume 5, Issue 13

This issue features explores treating older patients with frailty, discusses the management of primary mediastinal B-cell lymphoma, and more.